With approximately 2 m², the human skin is the largest organ of the human body and it contains about 1/3 of the blood. The skin protects the body from outside debris and microorganisms and keeps the fluids inside. However, it is not an impermeable layer; relatively small substances with the right chemical and physical properties can penetrate it. Transdermal patches (TTS) use this “weakness” to be effective. In contrast to orally used medications like pills, pharmaceuticals administered via TTS will not pass through the stomach and other intestines and therefore will not change its chemical composition. Also, a TTS releases its substance constantly over a long period of time – ideal for patients that tend to forget to take their medication on time.

The Innovative-Injections-Systems (IIS) company from Andernach/Germany has specialized in developing micro-needles and needle-less injection systems. Such systems are more flexible and are universally usable, states IIS managing director Mr. Stefan Henke. “Needle-less systems can be adjusted for its viscosity, penetration depth and its application volume. This secures high quality standards and reproducibility for administrating purposes”. The needle-free injection system uses a stamp-piston-system. It works with high-tech-jets to spray the aseptic liquid or drug solution with high pressure in less than one second under the skin. The micro-needle-injection system injects microscopically small needles from 100µm to 1000µm in length into the upper layer of the skin; it is pain free because no nerve endings are touched. The needles can consist of different materials like ceramics, steel, polymeric or silicon; the active substance can be released by micro-pores or dissolvable needles. The application of active substances with higher molecular weight like proteins, peptides and vaccines is imaginable. Samples for clinical testing takes are developed and manufactured at the IIS R&D Center in Andernach.